Opendata, web and dolomites

iSTantibody SIGNED

An innovative & seamless approach for the mass spectrometry analysis of monoclonal antibodies

Total Cost €


EC-Contrib. €






 iSTantibody project word cloud

Explore the words cloud of the iSTantibody project. It provides you a very rough idea of what is the project "iSTantibody" about.

preomics    guarantee    multiplexed    translates    consuming    tight    safety    worldwide    company    remarkable    protocols    gt    free    liquid    ist    spectrometry    forecasted    portfolio    2022    creation    plugged    companies    final    pharma    eliminating    mass    reproducible    biopharma    benefit    contaminants    poorly    volume    mabs    possibility    monoclonal    seize    employability    consequent    context    easily    complicated    patients    ahead    advantages    effectiveness    streamlined    standard    date    characterised    purity    diseases    consumables    preparations    pitfalls    scientists    antibodies    tackles    patented    manifold    opening    customers    shorten    proprietary    preparation    performed    13    seeking    handling    perspectives    therapeutic    drawing    innovative    market    proteomics    staff    automated    million    consists    95    jobs    platforms    2026    significantly    15    cagr    broad    time    purification    notably    simplify    benefits    billion    istantibody    12    revenues    revolutionise    german    kit    scientific    innovation    technique    tools    ms    panel    sensitivity    skilled    young   

Project "iSTantibody" data sheet

The following table provides information about the project.


Organization address
postcode: 82152
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PREOMICS GMBH DE (PLANEGG MARTINSRIED) coordinator 50˙000.00


 Project objective

Therapeutic monoclonal antibodies (mAbs) are innovative therapeutic tools that are currently drawing the attention of biopharma companies for their effectiveness against a broad panel of diseases. To guarantee safety for patients, tight control over the purity of mAbs preparations is crucial. The presence of contaminants in mAbs preparations can be assessed using mass spectrometry (MS), a technique characterised by remarkable sensitivity, but which requires a time-consuming, complicated and poorly reproducible sample preparation. Notably, at today’s date, this process cannot be automated or multiplexed: it has to be performed by highly skilled scientific staff, and - importantly - it cannot be easily “plugged in” the streamlined production approaches of pharma companies. PreOmics is a young German company seeking to revolutionise the MS proteomics market with its proprietary technology portfolio. Through the iSTantibody project, PreOmics translates its patented iST technology in the context of mAbs MS analysis and tackles the current pitfalls of mAbs sample preparation. Its final goal consists of a kit to simplify and shorten MS sample preparation by > 95% compared to standard protocols, eliminating the need for skilled scientists and allowing MS sample purification on automated liquid handling platforms. The advantages for potential customers are manifold – notably, significantly reduced costs, and the consequent possibility to free resources for mAbs development. The target sector of iSTantibody is the ever-growing market for MS sample preparation consumables, which is forecasted to reach a volume of € 1.3 billion worldwide in 2022, at a CAGR of 12%. The benefit of the iSTantibody project will produce remarkable benefits for PreOmics, both in terms of increased revenues ( € 15.3 million in 2026), employability (creation of 13 jobs) and innovation potential, opening new market perspectives and allowing PreOmics to seize more opportunities in the years ahead.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ISTANTIBODY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ISTANTIBODY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

GREEN WHS (2019)


Read More  

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

NAAS (2019)

NaaS - Newsroom as a service

Read More